Review articleFactors and strategies for improving buccal absorption of peptides
Introduction
Peptides are currently emerging as a major class of therapeutic drugs. Many are endogenous compounds regulating endocrine and other physiological processes in the body. Oligopeptides with less than ten amino acids are not readily absorbed through the gastrointestinal tract because of their high degradation by proteolytic enzymes or their sensitivity to acidic media. Therefore, they are usually not suitable for oral administration, and are mostly delivered by parenteral administration and due to their short biological half-life, repeated injections are often required. Non-parenteral routes of administration need to be developed in order to minimize side effects produced by constant injection. Nasal, ocular, vaginal, rectal and buccal mucous membranes have all been evaluated as potential alternative routes for peptide absorption. Mucosal delivery was found to be much less efficient than parenteral administration due to a combination of poor membrane permeability and metabolization at the site of absorption [1]. However, the buccal route has the advantage of avoiding the first-pass effect and non-exposure of the drug to the gastro-intestinal tract secretions. Furthermore, there are few proteolytic enzymes as compared to oral administration [2] and in addition, the buccal mucosa is highly vascularized.
To date, a wide variety of polypeptidic drugs have been evaluated for buccal absorption [3]. Some of these include gastrointestinal peptides (secretin, substance P), pancreatic hormones (insulin, glucagon), anterior pituitary polypeptides (adrenocorticotropins, growth hormone), posterior pituitary oligopeptides (oxytocin, vasopressin and their analogues), hypothalamic-releasing-hormones (protirelin, gonadorelin, growth hormone-releasing factor hormone, somatostatin) and their derivatives (e.g. the gonadorelin agonists, buserelin, histrelin and nafarelin), as well as enkephalins, calcitonin and interferons [4], [5], [6]. Peptide absorption is limited because of their instability, low diffusivity (due to their molecular weight and hydrophilicity) and rapid metabolism. Other factors such as immunogenicity, biocompatibility, aggregation and adsorption may also affect transport [7]. Chemical modification can be essential in order to improve stability by minimizing enzymatic cleavage. In addition, small peptides may be derivatized to produce prodrugs which possess favourable physico-chemical properties in comparison to the parent compound by rendering the peptide more lipophilic thus facilitating absorption [8], [9]. Bioreversible derivatization may protect small peptides against degradation by peptidases present at the mucosal absorption barrier. Another promising approach is the use of novel permeation enhancers in order to minimize irritation to the mucosal membranes. However, on account of the buccal mucosa's ability of rapid recovery, the toxicological issue with respect to absorption enhancers may not be as significant a factor as with other mucosal sites [10], [11], [12].
The accessibility of this absorption site over other sites and the high acceptance by the patient also favour the buccal mucosa as a site for systemic drug delivery.
Section snippets
Molecular weight and size
Molecular weight and size influence the diffusivity of the drug through the epithelial layer. As a general rule, very large molecules have lower diffusivities. Indeed, small molecules (<75–100 Da) appear to cross the mucosa barrier rapidly [13]. However, permeability falls off markedly molecular size increases. Several authors have investigated the effects of molecular weight upon mucosal absorption of various hydrophilic compounds [14], [15], [16]. It was found that the apparent permeability
Different classes of promoters used for buccal delivery
Relatively few studies have been carried out on the effect of absorption enhancers on peptide transport across buccal mucosa [88]. Most have only shown limited success (summarized in Table 4). The enhancers belong to various chemical classes including surfactants (anionic and non-ionic), bile salts, chelators, fatty acids, and alcohols.
The degree of enhancement depended on a number of factors, including the characteristics of the permeant, the composition of the delivery vehicle, and whether
Conclusions
Buccal delivery has many advantages, including the avoidance of hepatic first-pass metabolism, the membrane is robust and readily accessible and has high patient compliance and it certainly offer to the pharmacologist and clinicians the opportunity to deliver peptides. However, as the buccal mucosa is an effective permeability barrier, several strategies have been proposed to improve absorption. A number of factors define and limit the absorption of drugs from the buccal mucosa, including the
References (179)
- et al.
Recent advances in buccal drug delivery and absorption - in vitro and in vivo studies
J. Control. Release
(1999) - et al.
The potential of cyclodextrins as absorption enhancers in nasal delivery of peptide drugs
J. Control. Release
(1994) - et al.
Buccal delivery for peptide drugs
J. Control. Release
(1992) - et al.
Buccal drug absorption. I. Comparative levels of esterase and peptidase activities in rat and hamster buccal and intestinal homogenates
Int. J. Pharm.
(1988) Permeability of the rat oral mucosa to organic solutes measured in vivo
Arch. Oral Biol.
(1984)- et al.
Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity
J. Pharm. Sci.
(1987) - et al.
Mechanisms of nonelectrolyte penetration across dog and rabbit oral mucosa in vitro
Arch. Oral Biol.
(1981) - et al.
Oral administration of peptides: study of a glycerolipidic prodrug
Int. J. Pharm.
(1995) - et al.
Correlation of drug absorption with molecular surface properties
J. Pharm. Sci.
(1996) - et al.
Biophysical model approaches to mechanistic transepithelial studies of peptides
J. Control. Release
(1990)
The effect of drug charge type and charge density on corneal transport
Int. J. Pharm.
Nasal delivery of progestational steroid in ovariectomized rabbits. II. Effect of penetrant hydrophilicity
Int. J. Pharm.
Mechanism of nasal absorption of drugs II: absorption of l-tyrosine and the effect of structural modification on its absorption
J. Pharm. Sci.
Enhanced delivery of ketobemidone through porcine buccal mucosa in vitro via more lipophilic ester prodrugs
Int. J. Pharm.
Buccal absorption of ketobemidone and various ester prodrugs in the rat
Int. J. Pharm.
How structural features influence the biomembrane permeability of peptides
J. Pharm. Sci.
Enhancement of intestinal peptide absorption
J. Control. Release
Systemic delivery of therapeutic peptides and proteins
Int. J. Pharm.
In vitro permeability of porcine oral mucosa after epithelial separation, stipping and hydratation
Arch. Oral Biol.
The permeability of keratinized and nonkeratinized oral epithelium to horseradish peroxidase
J. Utrastruct. Res.
The permeability of keratinized and nonkeratinized oral epithelium to lanthanum in vivo
J. Utrastruct. Res.
Drug delivery via the mucous membranes of the oral cavity
J. Pharm. Sci.
Thin-layer chromatographic analyses of lipids in different layers of porcine epidermis and oral epithelium
Arch. Oral Biol.
Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery
Int. J. Pharm.
Comparison of enzymatic activities of tissues lining portals of drug absorption, using the rat as a model
Int. J. Pharm.
Absorption of glutathione from the gastro-intestinal tract
Biochim. Biophys. Acta
Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases
Life. Sci.
Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes
Life Sci.
Mechanisms, barriers and pathways of oral mucosal drug permeation
Adv. Drug Deliv. Rev.
Absorption of drugs from the human oral cavity
Int. J. Pharm.
Buccal absorption of protirelin: an effective way to stimulate thyrotropin and prolactin
J. Pharm. Sci.
Mechanism of oral permeation enhancer
Int. J. Pharm.
An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage
Int. J. Pharm.
Enzymatic barriers to peptide and protein absorption
Crit. Rev. Ther. Drug Carrier. Syst.
Peptidase activities in absorptive mucosae
Biochem. Soc. Trans.
Nasal drug delivery
Recent progress in protein and peptide delivery by noninvasive routes
Crit. Rev. Ther. Drug Carrier. Syst.
Advanced delivery systems for peptides and proteins – pharmaceutical
Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP)
Pharm. Res.
Prodrugs of peptides. 6. Bioreversible derivatives of Thyrotropin-Releasing Hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme
Pharm. Res.
Method to study the kinetics of oral mucosal drug absorption from solutions
J. Pharm. Pharmacol.
Influence of molecular weight and charge on nasal absorption of dextran and DEAE-dextran in rabbits
Int. J. Pharm.
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption
Pharm. Res.
Cultured buccal epithelium: an in vitro model derived from the hamster pouch for studying drug transport and metabolism
Pharm. Res.
Cyclopeptides as a novel class of transmucosal absorption enhancers
Proc. Int. Symp. Control. Release Bioact. Mater.
La muqueuse buccale en tant que barrière d'absorption des médicaments: caractéristiques structurales et dynamique de perméabilité, chapter 1
Iontophoretic delivery of a series of tripeptides across the skin in vitro
Pharm. Res.
Polymers for delivering peptides and proteins
Am. J. Hosp. Pharm.
Intraoral peptide absorption
Polymers for delivering peptides and proteins
Am. J. Hosp. Pharm.
Cited by (171)
Oromucosal delivery of macromolecules: Challenges and recent developments to improve bioavailability
2022, Journal of Controlled ReleasePeptide and peptide-based inhibitors of SARS-CoV-2 entry
2020, Advanced Drug Delivery ReviewsZero-order drug delivery: State of the art and future prospects
2020, Journal of Controlled ReleaseElectrospun nanofibers for the delivery of active drugs through nasal, oral and vaginal mucosa: Current status and future perspectives
2020, Materials Science and Engineering CCitation Excerpt :Besides the loss in crystallinity for samples, this study also demonstrated that decrease in the fiber diameter and increased porosity resulted in rapid dissolution. Liposomes have been recently utilized as a permeation barrier of the buccal mucosa [136]. Nevertheless, the colloidal liposomes have the inherent limitations of short residence and instability in the buccal cavity [137].
Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT)
2020, Nanomedicine: Nanotechnology, Biology, and Medicine